PODD Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 16.85% compared to Insulet's net margin of -19.35%. Insulet's return on equity of 43.11% beat iRhythm Technologies's return on equity of -112.03%.

Insulet has a consensus price target of $319.32, signalling upside risk potential of 2.79%. On the other hand iRhythm Technologies has an analysts' consensus of $137.33 which suggests that it could fall by -0.27%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are larger than iRhythm Technologies quarterly revenues of $158.7M. Insulet's net income of $100.7M is higher than iRhythm Technologies's net income of -$30.7M. Notably, Insulet's price-to-earnings ratio is 53.66x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 11.08x versus 6.98x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 16.85% compared to Insulet's net margin of 30.99%. Insulet's return on equity of 43.11% beat Intuitive Surgical's return on equity of 15.82%.

Insulet has a consensus price target of $319.32, signalling upside risk potential of 2.79%. On the other hand Intuitive Surgical has an analysts' consensus of $573.63 which suggests that it could grow by 6.92%. Given that Intuitive Surgical has higher upside potential than Insulet, analysts believe Intuitive Surgical is more attractive than Insulet.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Insulet's net income of $100.7M is lower than Intuitive Surgical's net income of $698.4M. Notably, Insulet's price-to-earnings ratio is 53.66x while Intuitive Surgical's PE ratio is 78.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 11.08x versus 22.35x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 16.85% compared to Insulet's net margin of -45.89%. Insulet's return on equity of 43.11% beat Masimo's return on equity of -39.91%.

Insulet has a consensus price target of $319.32, signalling upside risk potential of 2.79%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 16.29%. Given that Masimo has higher upside potential than Insulet, analysts believe Masimo is more attractive than Insulet.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are larger than Masimo quarterly revenues of $372M. Insulet's net income of $100.7M is higher than Masimo's net income of -$170.7M. Notably, Insulet's price-to-earnings ratio is 53.66x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 11.08x versus 4.30x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 16.85% compared to Insulet's net margin of -55.69%. Insulet's return on equity of 43.11% beat Tandem Diabetes Care's return on equity of -81.14%.

Insulet has a consensus price target of $319.32, signalling upside risk potential of 2.79%. On the other hand Tandem Diabetes Care has an analysts' consensus of $35.14 which suggests that it could grow by 52.93%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.474, suggesting its more volatile than the S&P 500 by 47.439%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are larger than Tandem Diabetes Care quarterly revenues of $234.4M. Insulet's net income of $100.7M is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, Insulet's price-to-earnings ratio is 53.66x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 11.08x versus 1.54x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.